Published in Nucleic Acids Res on May 21, 2014
Activating frataxin expression by repeat-targeted nucleic acids. Nat Commun (2016) 1.17
The role of the immune system in triplet repeat expansion diseases. Mediators Inflamm (2015) 0.85
Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels. J Clin Invest (2016) 0.85
RNA-mediated pathogenic mechanisms in polyglutamine diseases and amyotrophic lateral sclerosis. Front Cell Neurosci (2014) 0.82
Current understanding of the role of microRNAs in spinocerebellar ataxias. Cerebellum Ataxias (2014) 0.78
Molecular mechanisms underlying Spinocerebellar Ataxia 17 (SCA17) pathogenesis. Rare Dis (2016) 0.78
The first crystal structures of RNA-PNA duplexes and a PNA-PNA duplex containing mismatches-toward anti-sense therapy against TREDs. Nucleic Acids Res (2015) 0.76
Mutant CAG Repeats Effectively Targeted by RNA Interference in SCA7 Cells. Genes (Basel) (2016) 0.75
Precision medicine in spinocerebellar ataxias: treatment based on common mechanisms of disease. Ann Transl Med (2016) 0.75
Reduction of Huntington's Disease RNA Foci by CAG Repeat-Targeting Reagents. Front Cell Neurosci (2017) 0.75
Regulation of mRNA Translation by MID1: A Common Mechanism of Expanded CAG Repeat RNAs. Front Cell Neurosci (2016) 0.75
A brain-targeting lipidated peptide for neutralizing RNA-mediated toxicity in Polyglutamine Diseases. Sci Rep (2017) 0.75
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature (2001) 38.75
Most mammalian mRNAs are conserved targets of microRNAs. Genome Res (2008) 37.16
RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev (2001) 26.16
Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature (2010) 22.04
Specificity of microRNA target selection in translational repression. Genes Dev (2004) 21.14
Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature (2005) 19.15
Genome editing with engineered zinc finger nucleases. Nat Rev Genet (2010) 18.88
Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol (2003) 16.63
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75
Rational siRNA design for RNA interference. Nat Biotechnol (2004) 14.16
TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature (2005) 13.44
Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell (1992) 12.74
Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem (2010) 12.06
Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science (1997) 11.53
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev (2002) 10.71
Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature (1991) 9.89
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol (2011) 9.68
Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell (1997) 9.57
Trinucleotide repeat disorders. Annu Rev Neurosci (2007) 9.45
Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell (2005) 9.27
Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet (1993) 7.97
Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell (1997) 7.59
Small interfering RNA-induced transcriptional gene silencing in human cells. Science (2004) 7.29
Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 7.18
Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell (1998) 7.13
CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet (1994) 7.07
Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J (2000) 6.56
Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell (2000) 6.45
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol (2005) 5.99
Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol (2007) 5.78
Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol (2011) 4.98
Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nat Struct Mol Biol (2006) 4.93
RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol (2010) 4.86
In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature (2011) 4.81
RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A (2005) 4.79
Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA (2006) 4.72
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med (2004) 4.63
Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell (2006) 4.53
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A (2008) 4.53
Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron (2012) 4.48
Towards a transgenic model of Huntington's disease in a non-human primate. Nature (2008) 4.47
Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet (1994) 4.36
Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet (1996) 4.16
Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet (1997) 4.12
Ribonuclease H: the enzymes in eukaryotes. FEBS J (2008) 3.92
Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat Genet (2006) 3.87
The discovery of zinc fingers and their applications in gene regulation and genome manipulation. Annu Rev Biochem (2010) 3.75
RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov (2012) 3.70
Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev (2010) 3.69
Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol (2009) 3.66
Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science (2009) 3.62
Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A (2010) 3.58
Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. Nat Struct Mol Biol (2006) 3.46
ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell (2006) 3.39
Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet (1996) 3.26
Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet (2006) 3.23
Gene silencing using micro-RNA designed hairpins. RNA (2002) 3.21
Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood (2011) 3.21
Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nat Genet (1994) 3.17
Specific and potent RNAi in the nucleus of human cells. Nat Struct Mol Biol (2005) 3.16
Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet (1996) 3.07
Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A (2007) 3.07
Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A (2003) 3.00
Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet (2000) 2.95
Off-target effects by siRNA can induce toxic phenotype. RNA (2006) 2.89
Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell (2012) 2.83
Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med (2002) 2.81
RORalpha-mediated Purkinje cell development determines disease severity in adult SCA1 mice. Cell (2006) 2.80
Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet (2007) 2.77
Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet (1997) 2.77
RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature (2008) 2.74
Single-stranded siRNAs activate RNAi in animals. Cell (2012) 2.64
The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res (2003) 2.64
Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci (2008) 2.63
The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell (2002) 2.56
Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell (2012) 2.55
The impact of target site accessibility on the design of effective siRNAs. Nat Biotechnol (2008) 2.51
Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell (2003) 2.50
Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther (2009) 2.47
Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther (2005) 2.47
Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther (2012) 2.42
Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol (2009) 2.36
Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs. Nat Chem Biol (2005) 2.34
RNA structure of trinucleotide repeats associated with human neurological diseases. Nucleic Acids Res (2003) 2.34
A toxic monomeric conformer of the polyglutamine protein. Nat Struct Mol Biol (2007) 2.33
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.32
SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet (2001) 2.30
Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J Neurosci (2004) 2.29
Widespread expression of Huntington's disease gene (IT15) protein product. Neuron (1995) 2.29
A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res (2005) 2.27
Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem (1998) 2.23
Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.21
Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci U S A (2013) 2.21
Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol (2009) 2.19
Self-duplexing CUG repeats selectively inhibit mutant huntingtin expression. Nucleic Acids Res (2013) 0.82
Cooperation meets competition in microRNA-mediated DMPK transcript regulation. Nucleic Acids Res (2015) 0.77
Identifying proteins that bind to specific RNAs - focus on simple repeat expansion diseases. Nucleic Acids Res (2016) 0.76